Xtant Medical

News

Xtant Medical to announce Fourth Quarter and Full Year 2016 Results on March 9th, 2017

BELGRADE, Mont., March 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2016, after the close of the financial markets on Thursday, March 9, 2017. An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and John Gandolfo, Chie…
Read more

Xtant Medical Announces Appointment of Carl O’Connell to Permanent CEO

BELGRADE, Mont., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Carl O’Connell as the permanent CEO, effective February 17th, 2017. Mr. O'Connell previously served as president of Xtant since October of 2016 and was appointed as interim CEO on January 21st, 2017. Prior to joining Xtant Medical, Mr. O'Connell most recently served as the Vice P…
Read more

Xtant Medical CEO Dan Goldberger announces resignation

BELGRADE, Mont., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced that on January 21, 2017, Dan Goldberger resigned as Chief Executive Officer and as a Director of the Company and its subsidiaries to pursue other interests. Current President Carl O’Connell will serve as interim CEO while the Company’s Board of Directors cont…
Read more

XTNT Announces Issuance of PIK Notes

BELGRADE, Mont., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced the issuance of new convertible promissory notes on January 17, 2017 (the “New Notes”) to ROS Acquisition Offshore LP (“ROS”) and OrbiMed Royalty Opportunities II, LP (“OrbiMed”) for the following interest payments owed to them on January 15, 2017 …
Read more

XTNT Announces Closing of Registered Direct Offering

BELGRADE, Mont., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced the closing of a registered direct offering conducted without an underwriter or placement agent (the "Offering").  The Offering closed on January 17, 2017 and was with certain holders of its convertible promissory notes (“Indenture Notes”) to purchase a t…
Read more

FDA Clearance for the Xsert™ Lumbar Expandable Interbody System

xsert-image

Belgrade, MT, November 22, 2016 – Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Xsert Lumbar Expandable Interbody Syst…
Read more